Cancer cells consume large quantities of glucose and primarily use glycolysis for ATP production, even in the presence of adequate oxygen 1,2 . This metabolic signature (aerobic glycolysis or the Warburg effect) enables cancer cells to direct glucose to biosynthesis, supporting their rapid growth and proliferation 3,4 . However, both causes of the Warburg effect and its connection to biosynthesis are not well understood. Here we show that the tumour suppressor p53, the most frequently mutated gene in human tumours, inhibits the pentose phosphate pathway 5 (PPP). Through the PPP, p53 suppresses glucose consumption, NADPH production and biosynthesis. The p53 protein binds to glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme of the PPP, and prevents the formation of the active dimer. Tumour-associated p53 mutants lack the G6PD-inhibitory activity. Therefore, enhanced PPP glucose flux due to p53 inactivation may increase glucose consumption and direct glucose towards biosynthesis in tumour cells.
link to glycolysis, the regulation of the PPP in tumour cells remains unclear.
To investigate whether p53 modulates the PPP, we compared the oxidative PPP flux in isogenic p53 +/+ and p53 −/− human colon cancer HCT116 cells 11 . Cells were cultured in medium containing [2- 13 C]glucose, and the glucose metabolites were measured by nuclear magnetic resonance (NMR) spectroscopy. As shown in Fig. 1a , the absence of p53 resulted in a strong enhancement (∼50%) in oxidative PPP flux, indicating that p53 suppresses the PPP. The absence of p53 concomitantly led to a strong increase in glucose consumption, and this was observed in both HCT116 and mouse embryonic fibroblast (MEF) cells (Fig. 1b,c) . Inhibition of G6PD using either small interfering RNA (siRNA) or dehydroepiandrosterone (DHEA) reversed the increase in glucose consumption caused by p53 deficiency, but had little effect on glucose consumption in p53 +/+ cells (Fig. 1b,c) . These results indicate that p53 deficiency increases glucose consumption mainly through an enhanced PPP flux.
The lack of p53 also correlated with elevated lactate production ( Fig. 1d,e) . However, inhibition of G6PD in these cells increased, rather than decreased, lactate production, regardless of p53 status. Therefore, glucose flux through the PPP may itself lower lactate production. The suppression of lactate production may be related to the ability of p53 to decrease glycolysis 8 or increase oxidative phosphorylation 9 . The PPP plays a significant role in the production of cellular NADPH. The lack of p53 led to a strong increase in the NADPH level in HCT116 cells (∼2-fold, Fig. 2a) . Similarly, knocking down p53 in U2OS cells with small hairpin RNA (shRNA) strongly increased NADPH levels ( Supplementary Fig. S1a ). Treatment with G6PD siRNA minimized the difference in NADPH levels between p53-proficient and -deficient cells. To verify the cell culture findings in animals, we compared the NADPH levels in various tissues from p53 −/− and p53 +/+ mice. The tissues from p53 −/− mice-including heart, liver, kidney and lung-exhibited substantially P < 0.05 P < 0.0063 P < 0.01 P < 0.01 P < 0.02 P < 0.09 elevated NADPH levels, compared with those in the corresponding tissues from p53 +/+ mice (Fig. 2b) . The exception was found in the spleen. In this tissue, the activity of G6PD was very low (Fig. 2g) , and the PPP might not contribute substantially to the overall NADPH production. In contrast to p53 downregulation, overexpression of p53 led to a strong decrease in NADPH levels ( Supplementary Fig. S1b ).
NADPH is required for the biosynthesis of lipid. To assess the effect of p53 on lipid accumulation, we treated p53 +/+ and p53 −/− MEF cells with a combination of insulin, rosiglitazone, dexamethasone and isobutylmethylxanthine, which stimulates lipogenesis 12 . The p53
MEF cells showed enhanced lipid levels, compared with p53 +/+ MEF cells, as evaluated by Oil Red O staining (Fig. 2c) . The lack of p53 also resulted in higher levels of lipid in HCT116 cells ( Supplementary  Fig. S1c ). The difference in lipid accumulation between p53 +/+ and p53 −/− cells diminished on treatment with G6PD siRNA or DHEA. We also evaluated the effect of p53 on the formation of fat droplets in the liver. The liver of p53 −/− mice had a larger number of bigger fat droplets, compared with the liver of p53 +/+ mice (Fig. 2d) . Together, these results indicate that p53 inhibits NADPH production and lipid accumulation by lowering the glucose flux through the PPP. To investigate the mechanism by which p53 regulates the PPP, we assayed the activity of G6PD, a key regulatory point of the PPP. The lack of p53 correlated with a strong elevation in G6PD activity in both MEF and HCT116 cells ( Fig. 2e and Supplementary Fig. S1d,e) . Similarly, when p53 was knocked down in U2OS cells with shRNA, G6PD activity nearly doubled (Fig. 2f) . Furthermore, in mice tissues where G6PD activity could be adequately detected (for example liver, lung and kidney), the lack of p53 was associated with highly elevated G6PD activity (Fig. 2g) . Conversely, overexpression of wild-type p53 in the p53-deficient cell lines (H1299 and p53 −/− Mdm2 −/− MEF) caused a noticeable decrease in G6PD activity ( Supplementary Fig. S1f,g ). These results show that p53 suppresses G6PD activity.
In each of the cell lines and tissues that were examined, the levels of the G6PD protein remained unchanged when p53 was downregulated or overexpressed (Fig. 2a,b ,f and Supplementary Fig. S1 ). Moreover, p53 did not change the level of G6PD transcript (Fig. 3a) . To rule out the involvement of other p53 target genes in the inhibition of G6PD, we used an inhibitor of p53 transcriptional activity, pifithrin-α (PFTα; ref. 13 ). PFTα impeded p53-induced expression of p21, but did not restore p53-inhibited G6PD activity ( Fig. 3b and Supplementary Fig.  S2a ). We also used the protein synthesis inhibitor cycloheximide, alone or together with the DNA damaging agent doxorubicin. Treatment of p53 +/+ HCT116 cells with cycloheximide alone resulted in a lower level of p53, which was accompanied by a higher activity of G6PD (Fig. 3c ). Simultaneous treatment with cycloheximide and doxorubicin led to a stabilization of p53 above the basal level in unstressed cells, and a concurrent drop of G6PD activity below its basal level (Fig. 3c) . As controls, none of these treatments altered G6PD activity in p53 −/− HCT116 cells. In addition, the p53 mutant V122A, which has a transactivation activity comparable to or even higher than wild-type p53 dependent on the target gene 14 , failed to inhibit G6PD ( Supplementary Fig. S2b ). Moreover, we treated cells with the nuclear export inhibitor leptomycin B to prevent cytoplasmic accumulation of p53 (refs 15,16) . Leptomycin B reversed p53-mediated inhibition of G6PD ( Supplementary Fig. S2c-e) . Together, these results show that inhibition of G6PD by p53 is independent of transcription or translation and is a cytoplasmic, not nuclear, function of p53.
We next investigated whether p53 interacts with G6PD. Flag-tagged p53 specifically associated with enhanced green fluorescent protein (eGFP)-G6PD in vivo (Fig. 3d) . Similarly, endogenous p53 interacted with endogenous G6PD (Fig. 3e) . G6PD is a cytoplasmic protein, whereas p53 is present in both the cytoplasm and the nucleus, and consistently, the p53-G6PD interaction occurred in the cytoplasm ( Supplementary Fig. S2f-h ). This interaction was enhanced when cells were treated with the proteasome inhibitor MG132 doxorubicin, both of which stabilized p53 (Fig. 3d,e and Supplementary Fig. S2h ). The binding between p53 and G6PD is direct, as shown by a pulldown assay with purified recombinant proteins (Fig. 3f) . Analysis of the p53-G6PD binding in real time using surface plasmon resonance (BIAcore) showed that the dissociation constant (K d ) of p53 from G6PD was 173 ± 50 nM (Fig. 3g ). G6PD is a highly conserved protein, and human p53 interacted with G6PD proteins from both the bacterium Leuconostoc mesenteroides and the yeast Saccharomyces cerevisiae ( Supplementary Fig. S3a-c) .
Consistent with their direct interaction, purified wild-type p53 could inhibit purified G6PD in vitro (Fig. 4a,b) . In addition, introducing p53 into two S. cerevisiae strains, AH109 and EGY48, led to more than 60% inhibition of G6PD activity ( Supplementary Fig. S3d ,e). Expression of p53 also strongly reduced G6PD activity in Escherichia coli ( Supplementary Fig. S3f,g ).
To delineate the structural determinants for the inhibitory activity of p53 towards G6PD, we used a panel of p53 deletion mutants. The G6PD interaction domain was mapped to the carboxy-terminal region of p53 ( Fig. 3f and Supplementary Fig. S3b,c) . However, the C-terminal region alone was not sufficient for G6PD inhibition; the transactivation (TA) and DNA-binding domain (DBD) were also required (Fig. 4a,b and Supplementary Fig. S1f) . A further deletion analysis showed that within the C-terminal region, the negative regulatory (NR) domain, but not the tetramerization (TET) domain, was required for interaction with and inhibition of G6PD ( Supplementary Fig. S4a,b) .
The involvement of multiple domains of p53 in G6PD inhibition led us to test tumour-associated p53 mutants, most of which harbour missense mutations. Unlike wild-type p53, three p53 mutants (R175H, R273H and G279E) showed minimal or no activity in inhibiting G6PD ( Fig. 4c and Supplementary Figs S1g, S2b, S3g), even though at least two of them (R175H and R273H) retained the ability to bind to G6PD (Supplementary Fig. S4c ). Another tumour-associated, temperature-sensitive mutant (A138V) inhibited G6PD activity at the permissive temperature 32
• C, but not at the non-permissive temperature 37
• C. Moreover, the inhibitory effect at 32
• C was abolished with the introduction of R273H (Supplementary Fig. S4d) . To examine the effect of p53 mutants that are expressed at endogenous levels, we used a panel of SW480 cells, in which the endogenous p53 mutant (R273H/P309S) can be inducibly knocked down and, at the same time, exogenous p53 mutants containing either G245S or R248W, alone or in combination with alterations in activation domain 1 or 2, were inducibly expressed at levels comparable to the endogenous p53 mutant 17 . Replacement of the endogenous mutant p53 with exogenous mutants caused little or no changes in G6PD activity ( Supplementary Fig. S4e ). In contrast, a p53 mutant with increased thermodynamic stability 18 (N239Y), exhibited enhanced ability to inhibit G6PD (Fig. 4d) . As tumour-associated mutations impair the native conformation of p53 and the N239Y mutation stabilizes it, the inhibition on G6PD is probably attributed to the native conformation of p53.
We investigated how p53 inhibits G6PD activity. G6PD is in equilibrium of inactive monomer and active dimer 19, 20 . In both HCT116 and MEF cells, the lack of p53 led to a strong increase in G6PD dimer and a corresponding decrease in G6PD monomer (Fig. 4e) . In a transfection assay, p53 reduced the interaction of two differentially tagged G6PD proteins (Flag-G6PD and eGFP-G6PD) in a dose-dependent manner (Fig. 4f) . G6PD requires its substrate nicotinamide adenine dinucleotide phosphate (NADP + ) as the cofactor for the formation of holoenzyme, a property that ensures higher G6PD activity and thus more NADPH production when the NADPH/NADP + ratio drops 5 . NADP + diminished the interaction between G6PD and p53 in a dosedependent manner (Fig. 4g) , indicating that the binding of p53 to G6PD is incompatible with the binding of NADP + to G6PD. These results indicate that p53 may disrupt the formation of the dimeric G6PD holoenzyme.
The levels of p53 are kept low in unstressed cells owing to its rapid degradation in the proteasome. A semi-quantitative western blot assay showed the levels of cytoplasmic p53 were approximately 3% that of G6PD. The levels of p53 increased to ∼10% that of G6PD when p53 was stabilized by either MG132 or doxorubicin (Supplementary Fig. S5a ). Accordingly, most p53 molecules bound to G6PD in unstressed cells, but a small percentage of G6PD bound to p53, as shown by immunodepletion assays (Fig. 5a,b) . Only when p53 was stabilized by MG132 and doxorubicin did a significant portion of p53 molecules become separated from G6PD (Fig. 5b) .
The discrepancy between the amounts of p53 that stably bind to G6PD and the strong effect of p53 on overall G6PD activity raises the possibility that p53 is capable of inhibiting G6PD activity through transient interaction and at substoichiometric ratios. To test whether p53 can inhibit G6PD through transient interaction, we incubated lysates of p53 −/− MEF cells with recombinant p53 immobilized on beads and then separated the lysates from the beads. The treated lysates contained virtually all of the G6PD protein and undetectable amounts of p53 ( Fig. 5c and Supplementary Fig. S5b ), but showed much reduced G6PD activity (∼50%) and low levels of G6PD dimer (Fig. 5c,d ). In the same experiment, unconjugated control beads and beads conjugated with p53 DBD or p53 R273H protein all failed to inhibit G6PD activity and G6PD dimerization.
To assess whether one p53 molecule can inhibit multiple G6PD molecules, we first mixed extracts of p53 +/+ HCT116 cells treated with G6PD siRNA (with low G6PD, but normal p53 level) with extracts of p53 −/− HCT116 cells (with normal G6PD level, but no p53). The G6PD activity in the mix was substantially lower than the calculated average of these two extracts (Fig. 5e, column 4) , indicating that the small amounts of p53 protein in the former extracts could significantly inhibit the activity of a much larger amount of G6PD in the latter extracts. In a control experiment, when p53 +/+ HCT116 extracts were replaced with p53 −/− HCT116 extracts that were used, the G6PD activity in the mix was approximately the average of the two extracts that were used, as expected (Fig. 5e, column 6 ). We next mixed purified recombinant proteins at low molar ratios of p53 versus G6PD. At a ratio of 2.5% (approximately the ratio of these proteins in unstressed cells; Supplementary Fig. S5a ), p53 decreased G6PD activity by 20% (Fig. 5f ), indicating that one p53 molecule could inactivate up to eight G6PD molecules. This was probably an underestimate, because of the lability of p53 protein. The inhibition efficiency decreased at higher ratios of p53 versus G6PD, but increased at a lower molar ratio (Fig. 5f ). In contrast, R273H and R175H mutants failed to inhibit G6PD at any ratio examined (Fig. 5f ). Together, these results indicate that wild-type p53 may act as a catalyst to inactivate G6PD.
To evaluate cytoplasmic and nuclear pools of p53 in the inhibition of G6PD, we purified p53 proteins from these cellular compartments. Cytoplasmic p53 exhibited robust inhibitory activity towards G6PD. However, nuclear p53 protein showed minimal activity (Fig. 5g) . In the cell lysates, cytoplasmic p53 was mainly in monomeric form, whereas nuclear p53 was mostly in tetrameric form (Supplementary Fig. S5c ). This difference remained even after these proteins were purified and adjusted to the same concentration ( Supplementary Fig. S5d) . Therefore, the cytoplasmic and nuclear p53 proteins seem to be intrinsically different in their oligomerization status and their ability to inhibit G6PD.
This study identifies an important role for p53 in regulating G6PD. Through this regulation, p53 exerts a powerful surveillance on the metabolic pathways that are critical for both glucose catabolism and biosynthesis. The suppression of G6PD by p53 is evident in unstressed cells and is independent of transcription. As most cytoplasmic p53 associates with G6PD in unstressed cells (Fig. 5a,b) , inhibiting G6PD is probably a main function of cytoplasmic p53 in these cells. In stressed cells where p53 is stabilized, a portion of cytoplasmic p53 becomes free of G6PD and may carry out other functions previously attributed to cytoplasmic p53, such as the interaction with B-cell lymphoma 2 (Bcl-2) family proteins 21 . Notably, p53 can inhibit G6PD through transient interactions and at levels much lower than that of G6PD, indicating that p53 may act as a catalyst to induce conformational changes in G6PD. This function is attributed to the entire p53 protein, perhaps with the exception of the tetramerization domain, and seems to be specific to the p53 proteins originating from the cytoplasm, but not the nucleus. Metabolism is known to be controlled by allosteric interactions, covalent modifications of enzymes, and changes in their amounts. p53-induced conformational conversion of G6PD may represent a previously unknown mechanism of metabolic regulation. p53-mediated inhibition of the PPP probably dominates the effect of TIGAR (tumour protein 53 (TP53)-induced glycolysis and apoptosis regulator), a previously identified p53 target gene that stimulates the PPP (ref. 22) ; this is shown by the enhanced PPP flux and NADPH production in p53-deficient cells. Given the importance of p53 in suppressing the PPP, the prevalent inactivation of p53 in tumour cells probably accelerates glucose consumption, and, at the same time, directs glucose for rapid production of macromolecules by means of an increase in the PPP flux. Therefore, p53 inactivation not only contributes to the Warburg effect, but also links it to enhanced biosynthesis. 
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Antibodies and reagents. Antibodies against the following proteins/epitopes
were used with the sources and dilution ratios indicated in parentheses: GFP (Clontech; 1:4,000); p53 (DO-1, Oncogene, and Santa Cruz Biotechnology; 1:1,000); S. cerevisiae G6PD and Flag (M2) (Sigma); and human G6PD (Abcam; 1:4,000 and Sigma; 1:2,000). The following reagents were purchased from Sigma: Flag peptide, glutathione reductase, L. mesenteroides and S. cerevisiae G6PD proteins, DHEA, glucose-6-phosphate, 6-phosphogluconate, NADP + , insulin, rosiglitazone, dexamethasone, isobutylmethylxanthine, doxorubicin and [2-
13 C]glucose.
Plasmids. The DNA fragments corresponding to the full-length G6PD and p53
were amplified by polymerase chain reaction (PCR) from Marathon-Ready HeLa complementary DNA (Clontech), and cloned into p3 × Flag-Myc-CMV-24 (Sigma) and pEGFP-C1 (Clontech). The pGEX-2TK-p53 plasmid was provided by J. Kobarg (Centro de Biologia Molecular Estrutural, Laboratório Nacional de Luz Síncrotron, Brazil). p53 proteins tagged with a single Flag epitope were constructed in pRK5 (ref. 23). For expressing p53 in yeast, p53 was fused to the Gal4 DNA-binding domain in pGBKT7 and to the E. coli DNA binding protein LexA in pGlida (Clontech). For expressing p53 in bacteria, p53 was amino-terminally tagged with a Flag epitope in pET28(a). All deletion and point mutations were made by PCR and confirmed by DNA sequencing.
Analysis of the PPP and glycolysis in cells.
The flux through the oxidative branch of the PPP and glycolysis was assessed with carbon-13 NMR spectrometry as described previously 24 . p53 +/+ and p53 −/− HCT116 were cultured in triplicate 10 cm plates for three days to approximately 60-70% confluence. After being washed with medium containing no glucose, the cells were incubated with medium containing 10 mM [2-
13 C]glucose for 9 h. The rates of total glucose consumption and lactate formation were determined with a bench-top analyser (Nova Biomedical). Incorporation of 13 C in carbon 2 and 3 of lactate results from glucose metabolism through glycolysis and oxidative PPP, respectively. To determine the incorporation of 13 C into lactate at these carbon positions, the final medium from each culture was analysed in a 20-mm NMR tube with a 9.4 T spectrometer (Varian) at 100.66 MHz. A 90 • excitation pulse was applied every 6 s (fully relaxed), with broadband decoupling used only during 13 C data acquisition (no nuclear Overhauser effect enhancement). Spectra were acquired with 32,768 points, a spectral width of 25,000 Hz and 3,000 excitations. Free induction decays were apodized with exponential multiplication (1 Hz line broadening). The ratio of 13 C in carbons 2 (reflecting glycolytic flux) and 3 (reflecting oxidative PPP flux) of lactate and the rate of glucose consumption were used to estimate the oxidative PPP flux.
Glucose consumption and lactate production. Cells were seeded in culture plates and cultured for 6 h. The culture medium was then changed and cells were incubated for an additional 15 h. Glucose levels in the culture medium were measured using the Glucose (GO) Assay Kit (Sigma). Lactate levels were determined using a Lactate Assay Kit (Eton Bioscience).
Cell culture and gene knockdown with shRNA and siRNA. Cells were maintained in standard culture conditions. p53 −/− and p53 +/+ MEF cells were established from embryos of the corresponding mice generated by crossing p53 heterozygote mice (B6.129S2-Trp53tm1Tyj/J, The Jackson Laboratory). G6PD siRNAs were purchased from Invitrogen (Catalogue No. HSS103891 and HSS103892). G6PD shRNAs were purchased from Open Biosystem. The target sequence for G6PD shRNA #1 (Catalogue No. RHS3979-9595543) is 5 -GTCGTCCTCTATGTGGAGAAT-3 , and the target sequence for G6PD shRNA #4 (Catalogue No. RHS3979-9595544) is 5 -CAACAGATACAAGAACGTGAA-3 . Expression plasmid for p53 shRNA was made in a vector that co-expresses GFP (provided by D. C. Chan, California Institute of Technology, Pasadena, USA.). The targeted sequence for p53 is: 5 -GACTCCAGTGGTAATCTAC-3 (ref. 25) . siRNAs and shRNA plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen). Stable shRNA transfectants were selected in medium containing puromycin (1 µg ml −1 ) and pooled after culturing for 3-4 weeks. G6PD enzyme activity. G6PD enzyme activity was determined as described previously 26 . First, the combined activity of G6PD and 6-phosphogluconate dehydrogenase (6PGD), the second enzyme of the PPP, which also produces NADPH, was measured by the rate of conversion of NADP + to NADPH in the presence of glucose-6-phosphate (G6P). The activity of 6PGD alone was then measured by the conversion of NADP + to NADPH in the presence of 6-phosphogluconate (6PG). G6PD activity was calculated as the difference of these two activities. Cell lysates were added to the reaction buffer containing 50 mM Tris and 1 mM MgCl 2 , pH 8.1. Substrate concentrations used were: G6P and 6PG (200 µM), and NADP + (100 µM). Enzyme activities were normalized on the basis of protein concentration, which was determined by a BCA Assay Kit (Pierce). The data are expressed in arbitrary absorption units.
Immunoprecipitation and indirect immunofluorescence. Immunoprecipitation was carried out as described previously 27 . Briefly, cell lysates were made by sonication in buffer containing 20 mM HEPES (pH 7.8), 400 mM KCl, 5% glycerol, 5 mM EDTA, 0.4% NP40 and protease inhibitors, and pre-cleared by centrifugation. The supernatants were then diluted in 20 mM HEPES (pH 7.8), 50 mM KCl, 5% glycerol, 2.5 mM MgCl 2 , 0.05% NP40 and incubated with indicated protein A/G-Sepharose-bound antibodies for 4 h at 4 • C. Beads were pre-blocked with 2% BSA in PBS and 0.05% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulphonate (CHAPS) before immunoprecipitation. After incubation, beads were washed twice with lysis buffer, four times with ice-cold PBS and boiled in 2× loading buffer. Protein samples were resolved by SDS-PAGE.
The indirect immunofluorescence was carried out as described previously 23, 28 . Briefly, cells cultured on coverslips were treated separately with dimethylsulphoxide (DMSO) and etoposide (20 µM) for 24 h. Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 5 min, blocked with 5% BSA and incubated with antibodies as indicated, followed by a Texas-red-conjugated anti-rabbit IgG and a fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG antibody. The cells were mounted with 4,6-diamidino-2-phenylindole (DAPI)-containing medium (Vector Laboratories) and the images were acquired with a confocal microscope.
Protein purification. Flag-tagged G6PD and p53 were expressed in H1299 cells or 293T cells. When indicated, cell lysates were separated into cytosolic and nuclear fractions. Proteins were purified using M2 beads, as previously described 23, 29 . For purifying Flag-G6PD, 10 µM NADP + was included in the lysis buffer. Glutathione S-transferase (GST)-p53 was expressed in DH5α cells after induction with 2 mM isopropyl-β-D-thiogalactoside (IPTG) at 37 • C, and purified by glutathione beads (Amersham Biosciences).
Surface plasmon resonance analysis of p53-G6PD interaction. Surface plasmon resonance analysis was carried out at 25 • C with a Pharmacia Biosensor BiAcore 3,000 instrument (BiAcore) according to the manufacturer's instructions. S. cerevisiae G6PD was immobilized on the surface of a CM5 sensor chip in 10 mM sodium acetate buffer (pH 4.5) and resulted in 8,000 response units. A reference surface was used as a blank to correct for instrumental and buffer effects without protein injection. The amount of protein bound to the sensor chip was monitored by the change in refractive index. Purified Flag-p53 was diluted, and run across each sensor surface at five different concentrations in a running buffer of PBS at a flow rate of 30 µl min −1 . Flag-p53 protein concentrations were 0.03-0.9 µM. Dissociation constants from five serial dilutions of each protein and other kinetic parameters were calculated using the BIA Evaluation software.
NADPH level. NADPH levels were determined as described previously 30 . Cell lysates were prepared in buffer containing 0.1 M Tris-HCl, pH 8.0, 0.01 M EDTA and 0.05% (v/v) Triton X-100, sonicated and centrifuged at (2,400g ) at 4 • C. The total levels of NADPH plus reduced nicotinamide adenine dinucleotide (NADH) in the lysates were assayed by spectrometry (Beckman DU 640 spectrophotometer, Beckman Coulter) at a wavelength of 341 nm. The levels of NADPH in the lysates were determined on the basis of the decrease in absorbance at 341 nm after NADH was converted to nicotinamide adenine dinucleotide (NAD) by glutathione reductase.
Lipid synthesis. Lipid accumulation was measured using Oil Red O staining, as described previously 12 . Briefly, cells were grown in medium supplemented with insulin (2 µM), dexamethasone (1 µM) and isobutylmethylxanthine (0.25 mM) for 2 d, and in medium supplemented with insulin and rosiglitazone (10 −7 M) for an additional 5 d. The medium was changed every other day. Cells were then fixed with 10% buffered formalin for 16 h at 4 • C and were stained with a filtered Oil Red O solution (0.5% Oil red O in isopropyl alcohol) for 2 h at room temperature.
Analysis of p53
+/+ and p53 −/− mice. Four-week-old p53 +/+ and p53 −/− mice (B6.129S2-Trp53tm1Tyj/J) were obtained from the Model Animal Research Center (Nanjing University, China) and were maintained on a regular diet. Tissues were excised for the measurement of the G6PD activity and NADPH level. Liver tissues were fixed in 10% formalin and paraffin-embedded. Sections were prepared and stained with haematoxylin and eosin. All animal experiments were carried out in accordance with the local Animal Care and Use Committee. together with Flag-p53 or a control vector. Flag-p53 was immuno-stained with an anti-Flag antibody followed by a Texas Red-conjugated secondary antibody, and DNA was stained with DAPI. The individual and merged images are shown. Scale bars, 10µm. (g) Co-localization of endogenous p53 and G6PD in the cytosol. U2OS cells were treated with etoposide (ETO, 20 mM) or vehicle (DMSO) for 24 h. Endogenous p53 was detected by a mouse anti-p53 antibody followed by a FITC-conjugated secondary antibody, and G6PD by a rabbit anti-G6PD antibody followed by a Texas Red-conjugated secondary antibody. Scale bars, 10µm. (h) Lysates from p53 +/+ HCT116 cells treated with MG132 (20 μM), Dox (2 μM), or vehicle (DMSO) were separated into cytosolic (Cyto) and nuclear (Nucl) fractions. Each fraction was immunoprecipitated with anti-p53 antibody or a control antibody (IgG). Top: inputs and immunoprecipitated proteins (IP) were analyzed by western blotting using antibodies for G6PD and p53. Bottom: tubulin and lamin A in the lysates were analyzed as controls for fractionation and sample loading. Cytosolic fraction was analyzed for p53 and G6PD expression along with the indicated amounts of purified Flag-p53 and Flag-G6PD protein standards by western blot. Protein bands were qualified by NIH Image software, and the ratios of p53 and G6PD in the extracts to the corresponding standards were calculated. Based on these ratios and the relative amounts of the p53 and G6PD protein standards, the p53/G6PD ratios in the cell lysates are calculated. (b) Lysates from p53 -/-MEF cells were first incubated with Flag-tagged p53 proteins immobilized on beads and control beads, and then were separated from the beads (Figs. 5c, d ). G6PD in the total cell lysates (TCL) (top panel), beads-bound G6PD and p53 proteins (top and middle panels), and p53 proteins in the extracts after bead-binding (Sups) (bottom panels) were analyzed by western blot along with the same amount of purified G6PD and p53 protein standards (Std). Shown at the bottom are the ratios of beads-bound G6PD versus p53, of G6PD on beads versus G6PD in total cell lysates, and of p53 versus G6PD in the Sups after binding. Note that amounts of G6PD stably associated with immobilized p53 were minimal, while the amounts of wild type p53 released from beads were below detection. Asterisk indicates a non-specific band. (c) Cytosolic and nuclear fractions of p53 +/+ and p53 -/-HCT116 cells were treated with and without the chemical cross-linker DSS. Cell lysates were analyzed with western blot. Tubulin and LaminA in untreated lysates were analyzed as controls for fractionation and sample loading. p53 monomer, dimer, and tetramer are indicated. (d) Flag-p53 purified from cytosolic (C), nuclear (N), and total (T) lysate fractions (Fig. 5g) was treated with or without DSS, and examined by western blot. Figure S6 Full scans of western data. *Non-specific bands
